Barinthus Biotherapeutics (BRNS) Retained Earnings (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Retained Earnings came in at $394.5 million in Q1 2026, up 253.32% YoY from $111.7 million in Q1 2025, and up 229.73% on a QoQ basis from -$304.1 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Retained Earnings (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Retained Earnings data on file, last reported at $394.5 million in Q1 2026.
- Quarterly Retained Earnings rose 253.32% year-over-year to $394.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $394.5 million (up 253.32% YoY) and the FY2025 annual result came in at -$304.1 million, down 177.28% from the prior year.
- Retained Earnings advanced to $394.5 million in Q1 2026, from -$304.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $394.5 million in Q1 2026 to a low of -$304.1 million in Q4 2025.
- A 5-year average of $57.0 million and a median of -$106.0 million in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 449.5% in 2022, down 571.96% in 2022.
- Tracing BRNS's Retained Earnings over 5 years: stood at $379.5 million in 2022, then plunged by 146.53% to -$176.6 million in 2023, then jumped by 322.82% to $393.5 million in 2024, then tumbled by 177.28% to -$304.1 million in 2025, then soared by 229.73% to $394.5 million in 2026.
- The last three Retained Earnings figures came in at $394.5 million (Q1 2026), -$304.1 million (Q4 2025), and $393.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | Barinthus Biotherapeutics | 25.29 Mn | 25.29 Mn | - | 394.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 394.93 Mn |
| Mar 31, 2026 | 394.50 Mn |
| Dec 31, 2025 | -304.09 Mn |
| Sep 30, 2025 | 393.25 Mn |
| Jun 30, 2025 | 393.66 Mn |
| Mar 31, 2025 | -257.31 Mn |
| Dec 31, 2024 | 393.47 Mn |
| Sep 30, 2024 | 391.88 Mn |
| Jun 30, 2024 | -209.00 Mn |
| Mar 31, 2024 | -192.10 Mn |
| Dec 31, 2023 | -176.59 Mn |
| Sep 30, 2023 | -159.30 Mn |
| Jun 30, 2023 | -145.23 Mn |
| Mar 31, 2023 | -121.40 Mn |
| Dec 31, 2022 | 379.50 Mn |
| Sep 30, 2022 | -82.05 Mn |
| Jun 30, 2022 | 375.84 Mn |
| Mar 31, 2022 | -105.99 Mn |
| Dec 31, 2021 | -108.59 Mn |
| Sep 30, 2021 | -93.47 Mn |